Wasley A, Alter MJ: Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000, 20 (1): 1-16. 10.1055/s-2000-9506.
CAS
PubMed
Google Scholar
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002, 347 (13): 975-982. 10.1056/NEJMoa020047.
CAS
PubMed
Google Scholar
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001, 358 (9286): 958-965. 10.1016/S0140-6736(01)06102-5.
CAS
PubMed
Google Scholar
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011, 364 (25): 2405-2416. 10.1056/NEJMoa1012912.
CAS
PubMed
Google Scholar
Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011, 364 (13): 1195-1206. 10.1056/NEJMoa1010494.
CAS
PubMed
PubMed Central
Google Scholar
El-Sarag HB, Kunik M, Richardson P, Rabaneck L: Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002, 123: 476-482. 10.1053/gast.2002.34750.
Google Scholar
Yovtcheva SP, Rifai MA, Moles JK, Linden BJV: Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics. 2001, 42: 411-415. 10.1176/appi.psy.42.5.411.
CAS
PubMed
Google Scholar
Horikawa N, Yamazaki T, Izumi N, Uchihara M: Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psych. 2003, 25: 34-38. 10.1016/S0163-8343(02)00239-6.
Google Scholar
Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P: Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics. 2010, 51 (5): 401-408.
CAS
PubMed
PubMed Central
Google Scholar
Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P: A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord. 2007, 103: 83-90. 10.1016/j.jad.2007.01.007.
CAS
PubMed
Google Scholar
Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD: A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002, 7 (9): 942-947. 10.1038/sj.mp.4001119.
CAS
PubMed
Google Scholar
Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willnebring ML: Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psych. 2004, 26: 237-240. 10.1016/j.genhosppsych.2004.01.003.
Google Scholar
Ademmer K, Beutel M, Bretzel R, Jaeger C, Reimer C: Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C. Psychosomatics. 2001, 42 (4): 365-367. 10.1176/appi.psy.42.4.365.
CAS
PubMed
Google Scholar
Sockalingam S, Links PS, Abbey SE: Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. J Viral Hepat. 2011, 18 (3): 153-160. 10.1111/j.1365-2893.2010.01393.x.
CAS
PubMed
Google Scholar
Schaefer M, Hintzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, Sarkar R, Friebe A, Heinz A, Kluschke M: Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007, 46: 991-998. 10.1002/hep.21791.
CAS
PubMed
Google Scholar
Neri S, Bertino G, Petralia A, Giancarlo C, Rizzotto A, Calvagno GS, Mauceri B, Abate G, Boemi P, Di Pino A: A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J Clin Gastroenterol. 2010, 44 (9): e210-217. 10.1097/MCG.0b013e3181d88af5.
CAS
PubMed
Google Scholar
Moore DJ, Blackstone K, Woods SP, Ellis RJ, Atkinson JH, Heaton RK, Grant I: Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care. 2012, 24 (12): 1504-1513. 10.1080/09540121.2012.672718.
PubMed
PubMed Central
Google Scholar
Vertex Pharmaceuticals Inc: Incivek (telaprevir) Product Monograph. 2012, Cambridge, MA: Vertex Pharmaceuticals Incorporated
Google Scholar
Merck Canada Inc: Victrelis (boceprevir) Product Monograph. January 16, 2013, Kirkland, QC: Merck Canada Inc
Google Scholar
Kunze A, Huwyler J, Camenisch G, Gutmann H: Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol. 2012, 84 (8): 1096-1102. 10.1016/j.bcp.2012.07.032.
CAS
PubMed
Google Scholar
Guengerich FP: Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006, 8 (1): E101-111. 10.1208/aapsj080112.
CAS
PubMed
PubMed Central
Google Scholar
Flockhart DA, Tanus-Santos JE: Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002, 162 (4): 405-412. 10.1001/archinte.162.4.405.
CAS
PubMed
Google Scholar
Kipp G, Mohammad R, Lin A, Johnson H: Evaluation of pharmacist identified and mitigated drug-drug interactions in hepatitis C virus infected patients starting telaprevir or boceprevir. The 63rd Annual Meeting of the American Association for the Study of Liver Diseases. 2012, Boston, MA
Google Scholar
Hulskotte EGJ, Feng H-P, Xuan F, van Zutven M, O’Mara E, Youngberg S, Wagner JA, Butterton JR: Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir. Clin Infect Dis. 2013, 56 (5): 718-726. 10.1093/cid/cis968.
CAS
PubMed
Google Scholar
Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, Chave JP, Cavassini M, Bernasconi E, Calmy A: Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010, 15 (3): 413-423. 10.3851/IMP1540.
CAS
PubMed
Google Scholar
Sockalingam S, Abbey SE: Managing depression during hepatitis C treatment. Can J Psychiatry. 2009, 54 (9): 614-625.
PubMed
Google Scholar
Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, Foster GR, Kautz A, Forton D, Pariante CM: Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement. J Hepatol. 2012, 57 (6): 1379-1390. 10.1016/j.jhep.2012.07.037.
PubMed
Google Scholar
Ramasubbu R, Taylor VH, Saaman Z, Sockalingham S, Li M, Patten S, Rodin G, Schaffer A, Beaulieu S, McIntyre RS: The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry. 2012, 24 (1): 91-109.
PubMed
Google Scholar
Baraldi S, Hepgul N, Mondelli V, Pariante CM: Symptomatic treatment of interferon-alpha-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol. 2012, 32 (4): 531-543. 10.1097/JCP.0b013e31825d9982.
CAS
PubMed
Google Scholar
Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009, 11 (3): 225-255. 10.1111/j.1399-5618.2009.00672.x.
CAS
PubMed
Google Scholar
Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M: Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011, 365 (11): 1014-1024. 10.1056/NEJMoa1014463.
CAS
PubMed
Google Scholar
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A: Telaprevir for retreatment of HCV infection. N Engl J Med. 2011, 364 (25): 2417-2428. 10.1056/NEJMoa1013086.
CAS
PubMed
Google Scholar
Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010, 376 (9742): 705-716. 10.1016/S0140-6736(10)60934-8.
CAS
PubMed
Google Scholar
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N: Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011, 364 (13): 1207-1217. 10.1056/NEJMoa1009482.
CAS
PubMed
PubMed Central
Google Scholar
Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Helnze L, Spengler U, Schlaepfer T, Relmer J, Bugglsch P: Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease. Ann Intern Med. 2012, 157: 94-103. 10.7326/0003-4819-157-2-201207170-00006.
PubMed
Google Scholar
Gleason OC, Fucci JC, Yates WR, Philipsen MA: Preventing relapse of major depression during interferon-alpha therapy for hepatitis C–A pilot study. Dig Dis Sci. 2007, 52 (10): 2557-2563. 10.1007/s10620-006-9729-5.
CAS
PubMed
Google Scholar
Hulskotte EGJ, Gupta S, Xuan F, van Zutven MGJA, O'Mara E, Galitz L, Wagner JA, Butterton JR: Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. Global Antiviral Journal. 2011, 7 (1): 108-109. abstract
Google Scholar
Van Heeswijk RPG, Boogaerts G, De Paepe E, Van Solingen-Ristea R, Garg V, Beaumont M: The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. Rev Antiviral Ther Infect Dis. 2010, 5: 12-13.
Google Scholar
Nichols AI, Behrle JA, Parks V, Richards LS, McGrory SB, Posener J, Patat A, Paul J: Pharmacokinetics, pharmacodynamics, and safety of desvenlafaxine, a serotonin-norepinephrine reupatke inhibitor. J Bioequiv Availab. 2013, 5: 1-
Google Scholar
Zhou SF, Lai X: An update on clinical drug interactions with the herbal antidepressant St. John's wort. Current drug metabolism. 2008, 9 (5): 394-409. 10.2174/138920008784746391.
CAS
PubMed
Google Scholar
Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E, Farci MG, Carpiniello B, Pariante CM: Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol. 2004, 18 (1): 41-46. 10.1177/0269881104040230.
CAS
PubMed
Google Scholar
Dieperink E, Leskela J, Dieperink ME, Evans B, Thuras P, Ho SB: The effect of pegylated interferon-alpha2b and ribavirin on posttraumatic stress disorder symptoms. Psychosomatics. 2008, 49 (3): 225-229. 10.1176/appi.psy.49.3.225.
CAS
PubMed
Google Scholar
Gleason OC, Yates WR, Philipsen MA, Isbell MD, Pollock BG: Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics. 2004, 45 (1): 29-33. 10.1176/appi.psy.45.1.29.
CAS
PubMed
Google Scholar
Gleason OC, Yates WR, Isbell MD, Philipsen MA: An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002, 63 (3): 194-198. 10.4088/JCP.v63n0304.
CAS
PubMed
Google Scholar
Gleason OC, Yates WR, Philipsen MA: Major depressive disorder in hepatitis C: an open-label trial of escitalopram. Prim Care Companion J Clin Psychiatry. 2005, 7 (5): 225-230. 10.4088/PCC.v07n0503.
PubMed
PubMed Central
Google Scholar
Swinson RP, Antony MM, Bleau P, Chokka P, Craven M, Fallu A, Katzman M, Kjernisted K, Lanius R, Manassis K: Clinical Practice Guidelines: Management of Anxiety DIsorders. Can J Psychiatry. 2006, 51 (8): 2-
Google Scholar
Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV: QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013, 346: f288-10.1136/bmj.f288.
PubMed
PubMed Central
Google Scholar
Lundbeck Canada Inc: Celexa (citalopram) Product Monograph. 2012, Montreal, QC: Lundbeck Canada Inc
Google Scholar
Lundbeck Canada Inc: Cipralex (escitalopram) Product Monograph. 2012, Montreal, QC: Lundbeck Canada Inc
Google Scholar
DeMaio W, Kane CP, Nichols AI, Jordan R: Metabolism studies of desvenlafaxine. J Bioequiv Availab. 2011, 3: 151-160.
CAS
Google Scholar
Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H: Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci. 2000, 54: 565-572. 10.1046/j.1440-1819.2000.00754.x.
CAS
PubMed
Google Scholar
Scalori A, Pozzi M, Bellia V, Apale P, Santamaria G, Bordoni T, Redaelli A, Avolio A, Parravicini P, Pioltelli P: Interferon-induced depression: prevalence and management. Dig Liver Dis. 2005, 37 (2): 102-107. 10.1016/j.dld.2004.09.018.
CAS
PubMed
Google Scholar
Huet PM, Villeneuve JP: Determinants of drug disposition in patients with cirrhosis. Hepatology. 1983, 3 (6): 913-918.
CAS
PubMed
Google Scholar
Kasserra C, Hughes E, Treitel M, Gupta S, O’Mara E: Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions [abstract 118]. 18th Conference on Retroviruses and Opportunistic Infections. 2011, Boston, USA
Google Scholar
Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, Van Heeswijk RPG: Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol. 2012, 52 (10): 1566-1573. 10.1177/0091270011419850.
CAS
PubMed
Google Scholar
Luo X, Van Heeswijk RPG, Alves K, Garg V: The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers [abstract PK_11]. Rev Antiviral Ther Infect Dis. 2011, 6: 13-
Google Scholar
Rifai MA: Hepatitis C treatment of patients with bipolar disorder: a case series. Prim Care Companion J Clin Psychiatry. 2006, 8 (6): 361-366. 10.4088/PCC.v08n0607.
PubMed
PubMed Central
Google Scholar
Powell-Jackson PR, Tredger JM, Williams R: Hepatotoxicity to sodium valproate: a review. Gut. 1984, 25 (6): 673-681. 10.1136/gut.25.6.673.
CAS
PubMed
PubMed Central
Google Scholar
Felker BL, Sloan KL, Dominitz JA, Barnes RF: The safety of valproic acid use for patients with hepatitis C infection. Am J Psychiatry. 2003, 160 (1): 174-178. 10.1176/appi.ajp.160.1.174.
PubMed
Google Scholar
Argikar UA, Remmel RP: Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica; the fate of foreign compounds in biological systems. 2009, 39 (5): 355-363. 10.1080/00498250902745082.
CAS
PubMed
Google Scholar
Schaffer A, McIntosh D, Goldstein BI, Rector NA, McIntyre RS, Beaulieu S, Swinson R, Yatham LN: The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012, 24 (1): 6-22.
PubMed
Google Scholar
Novartis Pharmaceuticals Canada Inc: Tegretol (Carbamazepine) Product Monograph. 2011, Dorval, Que: Novartis Pharmaceuticals Canada Inc
Google Scholar
Andreasen AH, Brosen K, Damkier P: A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia. 2007, 48 (3): 490-496. 10.1111/j.1528-1167.2007.00924.x.
CAS
PubMed
Google Scholar
Hachad H, Ragueneau-Majlessi I, Levy RH: New antiepileptic drugs: review on drug interactions. Ther Drug Monit. 2002, 24 (1): 91-103. 10.1097/00007691-200202000-00016.
CAS
PubMed
Google Scholar
Freudenreich O, Gandhi RT, Walsh JP, Henderson DC, Goff DC: Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. Psychosomatics. 2007, 48 (5): 405-411. 10.1176/appi.psy.48.5.405.
PubMed
Google Scholar
Sockalingam S, Shammi C, Powell V, Barker L, Remington G: Determining rates of hepatitis C in a clozapine treated cohort. Schizophr Res. 2010, 124 (1–3): 86-90.
PubMed
Google Scholar
Matthews AM, Huckans MS, Blackwell AD, Hauser P: Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders. Bipolar Disord. 2008, 10 (2): 266-270. 10.1111/j.1399-5618.2007.00472.x.
PubMed
Google Scholar
Telio D, Sockalingam S, Stergiopoulos V: Persistent psychosis after treatment with interferon alfa: a case report. J Clin Psychopharmocol. 2006, 26 (4): 446-447. 10.1097/01.jcp.0000227348.59912.5d.
Google Scholar
Thome J, Knopf U: Acute psychosis after injection of pegylated interferon alpha-2a. Eur Psychiatry. 2003, 18: 142-143. 10.1016/S0924-9338(03)00030-0.
CAS
PubMed
Google Scholar
Garcia-Pares G, Domenech C, Gil M: Psychosis induced by interferon-alpha. Psychosomatics. 2002, 43: 428-429. 10.1176/appi.psy.43.5.428.
PubMed
Google Scholar
Hoffman RG, Cohen MA, Alfonso CA, Weiss JJ, Jones S, Keller M, Condermarin JR, Chiu NM, Jacobson JM: Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics. 2003, 44: 417-420. 10.1176/appi.psy.44.5.417.
PubMed
Google Scholar
Schafer M, Boetsch T, Laakmann G: Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C. Addiction. 2000, 95 (7): 1101-1104.
CAS
PubMed
Google Scholar
Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, Demotes-Mainard J, Henry C: Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry. 2005, 66 (8): 1050-1057. 10.4088/JCP.v66n0814.
CAS
PubMed
Google Scholar
Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ: Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry. 2004, 161 (3): 429-435. 10.1176/appi.ajp.161.3.429.
PubMed
Google Scholar
Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M: A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004, 24 (1): 62-69. 10.1097/01.jcp.0000104913.75206.62.
CAS
PubMed
Google Scholar
Merck Canada Inc. MC: Saphris (asenapine) Product Monograph. 2013, Kirkland, QC: Merck Canada Inc
Google Scholar
Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L: The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 1997, 44 (5): 439-446.
CAS
PubMed
PubMed Central
Google Scholar
Spina E, de Leon J: Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007, 100 (1): 4-22. 10.1111/j.1742-7843.2007.00017.x.
CAS
PubMed
Google Scholar
English BA, Dortch M, Ereshefsky L, Jhee S: Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting. Curr Psychiatry Rep. 2012, 14 (4): 376-390. 10.1007/s11920-012-0284-9.
PubMed
PubMed Central
Google Scholar
AstraZeneca Canada Inc: Seroquel (quetiapine) Product Monograph. 2013, Mississauga, ON: AstraZeneca Canada Inc, April 16
Google Scholar
Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS: Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2013, 28 (1): 50-56. 10.1097/YIC.0b013e32835ac9da.
PubMed
Google Scholar
Liukkonen T, Sorjonen M, Jokelainen J, Timonen M: Treatment of hepatitis C with interferon-alpha and ribavirine in a patient with long-term clozapine treatment. Psychosomatics. 2008, 49 (1): 86-88.
PubMed
Google Scholar
Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002, 71 (2): 163-169. 10.1016/S0024-3205(02)01680-6.
CAS
PubMed
Google Scholar
Sylvestre DL, Clements BJ: Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007, 19 (9): 741-747. 10.1097/MEG.0b013e3281bcb8d8.
CAS
PubMed
Google Scholar
Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, Gallagher L, Storms M, Raffa JD, DeVlaming S: Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010, 22 (3): 270-277. 10.1097/MEG.0b013e32832a8c4c.
PubMed
Google Scholar
Luo X, Trevejo J, van Heeswijk RP, Smith F, Garg V: Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy. Antimicrob Agents Chemother. 2012, 56 (7): 3641-3647. 10.1128/AAC.00077-12.
CAS
PubMed
PubMed Central
Google Scholar
Sockalingam S, Blank D, Al Jarad A, Alosaimi F, Hirschfield G, Abbey SE: A comparison of depression screening instruments in hepatitis C and the impact of depression on somatic symptoms. Psychosomatics. 2011, 52 (5): 433-440.
PubMed
Google Scholar
Hulskotte EGJ, Hwa-Ping F, Bruce RD, Webster LR, Xuan F, O'Mara E, Wagner JA, Butterton JR: Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy [abstract PK_09]. 2012, Cambridge, MA: 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy, Rev Antiviral Ther Infect Dis 2012; 6:12
Google Scholar
Dbouk B, Arguedas MR, Sheikh A: Assessment of the PHQ-9 as a screening tool for depression in patients with chronic hepatitis C. Dig Dis Sci. 2008, 53: 1100-1106. 10.1007/s10620-007-9985-z.
PubMed
Google Scholar
Knott A, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M, Johnson JR, Thuras P, Ho SB: Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006, 101 (10): 2254-2262. 10.1111/j.1572-0241.2006.00731.x.
PubMed
Google Scholar
Huckans M, Mitchell A, Ruimy S, Loftis J, Hauser P: Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr Bull. 2010, 36 (1): 165-172. 10.1093/schbul/sbn065.
PubMed
Google Scholar
Sockalingam S, Blank D, Banga CA, Mason K, Dodd Z, Powis J: A novel program for treating patients with trimorbidity: hepatitis C, severe mental illness, and active substance use. Eur J Gastroenterol Hepatol. 2013, in press,
Google Scholar